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SUMMARY
The mechanisms by which immune checkpoint blockade modulates tumor evolution during 
therapy are unclear. We assessed genomic changes in tumors from 68 patients with advanced 
melanoma, who progressed on ipilimumab or were ipilimumab-naive, before and after nivolumab 
initiation (CA209-038 study). Tumors were analyzed by whole-exome, transcriptome, and/or T-
cell receptor (TCR) sequencing. In responding patients, mutation and neoantigen load were 
reduced from baseline, and analysis of intratumoral heterogeneity during therapy demonstrated 
differential clonal evolution within tumors and putative selection against neoantigenic mutations 
on-therapy. Transcriptome analyses before and during nivolumab therapy revealed increases in 
distinct immune cell subsets, activation of specific transcriptional networks, and upregulation of 
immune checkpoint genes that were more pronounced in patients with response. Temporal 
changes in intratumoral TCR repertoire revealed expansion of T-cell clones in the setting of 
neoantigen loss. Comprehensive genomic profiling data in this study provide insight into 
nivolumab mechanism of action.
eTOC
Mutation burden decreases with successful checkpoint blockade therapy in patients with 
melanoma, suggesting that selection against protective mutant neoepitopes may be a critical 
mechanism of action of Nivolumab
Riaz et al. Page 2
Cell. Author manuscript; available in PMC 2018 November 02.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Keywords
Melanoma; Tumor microenvironment; Tumor immune evasion; Immunotherapy; Nivolumab; 
Ipilimumab; Tumor mutation load/Tumor mutation burden; Neoantigen load; Clonal evolution/
Clonal selection; T-cell receptor repertoire
INTRODUCTION
Immune checkpoint inhibitors have demonstrated improved overall survival (OS) and 
progression-free survival (PFS) in the treatment of many different tumor types (Brahmer et 
al., 2015; Ferris et al., 2016; Hodi et al., 2016; Motzer et al., 2015; Robert et al., 2015). The 
underlying genomic features of a tumor can contribute to its response to checkpoint 
blockade, and increased tumor mutation load associates with survival benefit from both anti-
CTLA-4 and anti-PD-1 therapy in multiple malignancies (Hugo et al., 2016; Le et al., 2015; 
Rizvi et al., 2015; Rosenberg et al., 2016; Snyder et al., 2014; Van Allen et al., 2015). High 
tumor mutation load may increase the probability of generating immunogenic neoantigens, 
which facilitate recognition of a tumor as foreign (Riaz et al., 2016a; Schumacher and 
Schreiber, 2015). Thus, tumors with a high number of clonal neoantigens may be more 
likely to elicit effective immune responses (McGranahan et al., 2016).
Features of the tumor microenvironment (TME) also associate with response to checkpoint 
inhibitor therapy. Expression of PD-L1 in the TME associates with clinical response to anti-
PD-1/PD-L1 therapies in multiple tumor types (Herbst et al., 2014; Topalian et al., 2012). 
Baseline levels of tumor-infiltrating CD8+ T cells correlate with the likelihood of response, 
and may increase during therapy in responding but not progressing tumors (Topalian et al., 
2016; Tumeh et al., 2014). Further, the location of CD8+ T cells at the invasive margin of 
tumors may indicate an effective immune response (Chen et al., 2016; Spranger et al., 2015; 
Tumeh et al., 2014). The TME may limit extravasation of effector T cells into the tumor, 
diminish T-cell expansion, or reduce the viability of tumor-infiltrating lymphocytes (TILs) 
(Joyce and Fearon, 2015).
How checkpoint inhibitor-mediated immune activation modulates the mutational landscape 
of the tumor and the TME remains poorly understood. To characterize genomic changes, we 
performed comprehensive genomic analyses on melanoma samples pre- and post-nivolumab 
(Nivo; anti-PD-1 agent) therapy.
RESULTS
Genomic Characteristics of Tumors before Nivo Treatment
Pre-therapy biopsies from 68 patients were assessed by whole-exome sequencing (WES) at 
150× (mean depth: 168; range: 121–237) (Table S1). Thirty-five patients had previously 
progressed on ipilimumab (Ipi) therapy (Ipi-P); 33 patients were Ipi-naive (Ipi-N) (Table 
S2). In the patients with WES data, rates of response (RECIST v1.1-defined complete 
response [CR] or partial response [PR]) to Nivo were comparable in Ipi-N (21%) and Ipi-P 
(22%) patients. Median mutation load in the patient cohort was 183 mutations (range: 1–
7360; interquartile range: 44–433; Table S2,3) and did not differ significantly between Ipi-N 
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and Ipi-P patients (Figure 1A). Mutational subtypes of melanoma as defined by The Cancer 
Genome Atlas (TCGA) (Cancer Genome Atlas Network, 2015) did not differ in response to 
Nivo. There were more triple wild type (WT) patients in the Ipi-P cohort than the Ipi-N 
cohort (57% versus 33%, p = 0.06; Fisher’s exact test; Figure 1A).
Tumor and Clonal Mutation Load Are Associated with OS and Response in Nivo-Treated 
Ipi-N Patients
Tumor mutation load associated with OS in Ipi-N but not Ipi-P patients (Figures 1B and 
S1A), and Ipi-P patients tended to have lower numbers of clonal mutations (p = 0.08; Figure 
S1B). Stratification of patients by the number of clonal mutations improved the ability to 
predict survival and response of Ipi-N but not Ipi-P patients (Figures 1B, S1C and S1D). 
Mutation signatures may play a role in response to checkpoint blockade in NSCLC (Rizvi et 
al., 2015); however, here, no relationship between the proportion of mutations due to any of 
the known melanoma mutation signatures (e.g., UV or aging) (Alexandrov et al., 2013) and 
response to therapy was observed (Figure 1A).
No single gene mutations were significantly associated with response or resistance to 
therapy. SERPINB3/B4 gene mutations in melanoma samples associate with response to 
anti-CTLA-4 therapy (Riaz et al., 2016b), and here, five of six patients with SERPINB3/B4 
mutations had disease control (CR/PR or stable disease [SD]); however, this was not 
statistically significant, likely due to small numbers (p = 0.21; Fisher’s exact test). One 
patient with PR had a frame-shift alteration in B2M with corresponding loss of 
heterozygosity, alterations previously associated with acquired resistance to anti-PD-1 
therapy (Zaretsky et al., 2016). JAK1 and JAK2 mutations were not associated with 
resistance in this cohort (Figure 1A). No recurrent copy-number alterations as determined by 
TCGA associated with response; nor did copy-number alterations in interferon (IFN) genes 
on chromosome 9p (Figures S1E and S1F). However, the frequency of global genomic 
instability (Davoli et al., 2017) associated with OS in Ipi-P but not Ipi-N patients (Figure 
S1G).
Evolution of Tumors during Nivo Treatment
To determine if Nivo therapy affects tumor mutation load and intratumor heterogeneity, 
WES was performed on a subset (n = 41) of paired pre- and on-therapy biopsy samples 
(Table S4). Significant differences between pre- and on-therapy biopsies correlated with 
response (p = 5.87e–5; Mann–Whitney test for CR/PR versus progressive disease [PD]) 
(Figures 1C, S1H, and S1I). Among Ipi-N and Ipi-P responders, a reduction in mutation and 
neoantigen load was observed 4 weeks after initiation of Nivo, perhaps consistent with 
immunoediting (Tables S5A and S5B). To ensure that these observations were not solely due 
to changes in tumor purity after therapy, further deep sequencing (300×) was performed on 
responding tumors. In each case, many of the mutations seen in the pre-therapy samples 
were still detectable in on-therapy samples (Figures S2A–S2C). The proportion of mutations 
that remained detectable varied depending on response: the mean fraction of variants in on-
therapy samples was 19% for CR/PR (range: 1%–99%), 82% for SD (range: 2%–140%) and 
101% for PD (range: 33%–205%) (values greater than 100% indicate additional mutations 
beyond those in pre-therapy samples were detected). Power calculations, assuming a global 
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five-fold decrease in the variant allele frequency on-therapy (see Methods), demonstrated 
that the magnitude in change of mutation load could not be explained by changes in tumor 
purity alone (Figures S2D–S2F). There were four cases of focal loss of CDKN2A that 
appeared in on-therapy samples, all in patients with PD. In three of these patients, 
chromosome 9p deletions also included the nearby IFN gene cluster.
Subsequently, we examined association of changes in the clonal compositions of paired pre- 
and on-therapy tumor samples with response. The fraction of tumor cells carrying a variant 
(cancer cell fraction, CCF) in both pre- and on-therapy samples was estimated (see 
Methods) (Roth et al., 2014). The temporally related changes that occurred in the clonal 
composition of tumors differed between response groups. Patients with CR/PR had 
markedly high frequencies of tumor clonal and subclonal variants that decreased in 
prevalence after Nivo therapy and, in many cases, were not detected on-therapy (mutational 
contraction; see Methods; Figure 2A). The relative frequencies of single nucleotide 
variations (SNVs) undergoing mutational contraction were significantly less in patients with 
PD than SD (p = 0.01). In addition, the relative frequencies of novel SNVs detectable on-
therapy were significantly higher on a per-sample basis in patients with PD than SD (p = 
0.02), consistent with presumed mutational expansion and/or genetic drift (Figure 2B). Net 
genomic changes (defined as the difference of variants representing mutational contraction 
and mutational persistence [see Methods]) per sample strongly associated with response and 
OS, and this metric was superior to the temporal change in mutation load in predicting 
response (Figure 2C). Tumors from patients with SD were identified as an intermediate 
molecular phenotype between those with CR/PR and PD: 26% (5 of 19) of PD samples had 
>50% of SNVs with variant gain (SD: 0 of 13), while 38% (5 of 13) of SD samples had 
>50% of SNVs under variant loss (PD: 0 of 19) (Figure 2A).
Excluding patient 3, all patients with CR/PR consistently lost one or more clones on-
therapy; conversely, patients with SD and PD gained novel sets of mutations on-therapy 
(Figures 2A and 2D). For example, patient 27 (PD) and patient 10 (SD) both had a dominant 
clone, at least one smaller subclone at initiation of therapy, and the emergence of a novel 
subclone in the on-therapy sample. In addition, patient 10 had a subclone that was lost after 
treatment (Figure 2D). Losses were more common in patients with SD than PD. On 
aggregate, novel subclonal variants were often due to mutational signature 11, which has 
previously been associated with melanoma and exposure to temozolomide (Alexandrov et 
al., 2013), and in this setting, suggests that a specific type of repair process becomes 
dysfunctional due to immunotherapy-mediated stress (Figure S2G).
Transcriptome Analysis and Changes during Treatment
Pre-therapy Expression Analysis Identified Pre-existing Immune Programs in 
Responders and Expression Footprints of “Hot” versus “Cold” Tumors Based 
on Prior Immunotherapy Exposure—Baseline transcriptional programs using RNA 
sequencing (RNA-seq) were characterized and associations with clinical response 
investigated (n = 45; Table S4). Analysis of differentially expressed genes (DEGs) between 
patients with CR/PR and PD identified 189 DEGs (q < 0.20; Figure 3A). Highly expressed 
genes were immune-related, which suggests pre-existing immune recognition of the tumor; 
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however, Gene Ontology (GO) analysis using the Reactome database only identified high-
level categories such as T-cell activation and lymphocyte aggregation as enriched (q < 0.1; 
Figure S3A). Notably, this group included IL17RE, IL17RC and FGFR3 (Table S6A), which 
modulate the immune environment (Sweis et al., 2016). Next, pre-existing signatures of 
immune response were evaluated by immune deconvolution (see Methods). A pre-existing 
immunologically active or “hot tumor” environment was observed in all Ipi-P patients with 
CR/PR, whereas variable immunological activity was observed in Ipi-N patients with CR/PR 
(Figures 3B and S3B). No association between the previously reported IPRES gene 
signature and response was seen in this cohort or in another cohort previously described 
(Hugo et al., 2016) (Figure S3C).
On-therapy Genomic Contraction Phenotype Correlated with Pre-existing 
Immunity in Responders—We hypothesized that a molecular phenotype of response, 
such as tumor genomic contraction/persistence, ascertained at an early time-point, such as 4 
weeks (Figure 2C), may more strongly correspond to underlying biologic changes than 
would clinical assessments of response. Differential gene expression analysis between 
patients who had genomic contraction and genomic persistence was performed to examine 
pre-existing differences in immunity pre-therapy. In the cohort of 26 patients with paired 
WES and RNA-seq, 695 DEGs were observed (q < 0.10; Figure 3C and Table S6B), of 
which 565 had a fold change greater than two. Clustering analysis of all patients and other 
checkpoint-blockade-treated cohorts demonstrated that this set of immune-related genes 
stratified patient survival (Figure 3D).
Gene set enrichment analysis demonstrated enrichment of genes involved in PD-1 signaling, 
co-stimulation of the CD28 family, downstream T-cell receptor (TCR) signaling, IFN-γ, and 
IL-2 signaling (q < 0.1; Figure S3D). Although PD-1 signaling was enriched, neither 
PDCD1 (PD-1) nor CD274 (PD-L1) were differentially expressed. However, components of 
the TCR immunological synapse were enriched (e.g., CD3D/E/G, PTPN6, CD247, CD28, 
CD86). Notably, several HLA class II alleles were differentially regulated between the two 
groups, in addition to genes associated with PI3K-γ signaling by G protein–coupled 
receptors (Figures S3D and S3E).
On-therapy Analysis of Tumor Transcriptome—We subsequently hypothesized that 
anti-PD-1 therapy can induce tumor transcriptional and microenvironmental sculpting 
associated with response and therefore evaluated how the expression landscape of melanoma 
is altered during Nivo therapy. To identify expression changes indicative of a 
“pharmacologic response” to Nivo, expression of genes that significantly change on-therapy, 
regardless of response, were analyzed. 475 DEGs were identified in on-therapy samples (q < 
0.20; Figure 4A and Table S6C), most of which were associated with immune regulation as 
determined by Ingenuity Pathway Analysis (IPA) (Figure S4A). Many immune checkpoint 
genes increased in expression, regardless of response to therapy, including PDCD1 (PD-1), 
CD274 (PD-L1), CTLA-4, CD80 (CTLA-4-L), ICOS, LAG3, and TNFRSF9 (4-1BB).
Matched pre- and on-therapy samples were examined to determine whether relative 
differences in gene expression changes on-therapy could distinguish between patients whose 
disease was controlled and patients with PD. 2670 DEGs were identified between pre- and 
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on-therapy samples of responders and non-responders (q < 0.20; Figure 4B; Table S6D). 
Upregulated genes in responders involved a broader spectrum of immune-related genes than 
genes solely identified in pre-therapy samples (Figures S4B and S4C); including additional 
checkpoint-related genes (TNFRSF4 [OX40], TIGIT, HAVCR2 [TIM-3], and C10orf54 
[VISTA]), and genes involved in lymphocyte activation, chemotaxis and cytokine signaling, 
and immune cytolytic activity, consistent with previous findings (Das et al., 2015). 
Downregulated genes in responders involved pathways related to tumor growth, including 
neural and melanin pathways, cell-cycle regulation, mitotic division, and translation (Figure 
4C). Significantly more immune-related genes were selectively upregulated in responders 
than in non-responders (p = 6.17e–3 and p = 4.61e–4 for depletion in the inflammatory 
response and cytokine-mediated signaling pathways from GO, respectively).
Changes in immune subpopulations between pre-therapy and on-therapy samples were 
assessed by immune-deconvolution analysis (see Methods) and numerous changes in 
immune response among different tumors were observed. An increase in number of CD8+ T 
cells and NK cells, and a decrease in M1 macrophages, associated with response to therapy 
(Figure 4D).
T-Cell Repertoire Analysis and Immune Checkpoint Therapy
How Nivo therapy influences T-cell repertoires was examined by analysis of changes in the 
T-cell abundance, activation, and diversity. We also evaluated how these anti-PD-1-induced 
changes are affected by prior immunotherapy exposure. To study the dynamics of T-cell 
infiltration and repertoire diversity in response to Nivo, next-generation deep sequencing of 
TCR β-chain complementarity determining regions (CDR3s) (TCR-seq) was performed on 
tumor samples pre- and 4 weeks post-Nivo initiation (n = 34; Table S4). From these 
nucleotide sequences, the repertoire of amino acid motifs that determine the specificity of 
antigen-binding and their relative abundances were tabulated (see Methods). Due to the 
limited number of samples for which TCR-seq data was available, we grouped patients as 
those with benefit (CR, PR, and SD) or no benefit (PD).
Changes in T-Cell Tumor Infiltration and Activation Associated with Prior 
Treatment Status and Clinical Response—The fraction of TILs present within each 
tumor (the proportion of sample that is infiltrating lymphocytes) was assessed by both TCR-
seq and immunohistochemical (IHC) staining for CD3 on mostly non-overlapping cohorts of 
patients (Table S4). By both approaches, an increase in the fraction of TILs upon Nivo 
therapy was significantly greater among benefiting than non-benefiting Ipi-N but not Ipi-P 
patients (TCR-seq, p = 0.040; IHC, p = 0.023). Despite the differences in T-cell infiltration, 
increased cytolytic pathway genes (Rooney et al., 2015) as measured by RNA-seq were 
associated with benefit to Nivo in both Ipi-P and Ipi-N cohorts (p = 0.043 and p = 0.005; 
Figure 5A). Notably, there was no significant difference in TIL abundance pre-therapy 
between patients with benefit and no benefit, or between Ipi-N and Ipi-P cohorts (Figure 
S5A).
On-therapy Changes in Intratumoral T-Cell Repertoire Diversity Associated 
with Response Differentially between Ipi-P and Ipi-N Patients—The diversity of 
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the CDR3 repertoire can be characterized by the Shannon entropy metric, which has two 
components: the number of unique CDR3s (richness) and their equality of distribution 
(evenness) (see Methods). Pre-therapy, no significant difference in either of these metrics 
was observed between cohorts or response status (Figures S5B and S5C). On-therapy, the 
median fold change in the number of unique CDR3 sequences (richness) was significantly 
associated with benefit in Ipi-P but not Ipi-N patients (p = 0.016 versus p = 0.489; Figure 
5B). In contrast, the median change in T-cell evenness on-therapy was associated with 
benefit in Ipi-N but not Ipi-P patients (p = 0.036 versus p = 0.594; Figure 5B).
To refine interpretation of these findings with respect to the antigen-binding properties of the 
TCR repertoire, the diversity of the CDR3 amino acid sequences encoded by a single VJ 
cassette combination was analyzed individually for every observed VJ combination (see 
Methods). Notably, a significant decrease in median CDR3 evenness per VJ group on-
therapy was observed in Ipi-N but not Ipi-P patients (p = 0.006 versus p = 0.600 Figures 5C 
and 5D) and in benefiting but not non-benefiting patients (p = 0.003 versus p = 0.636; 
Figures 5D and S5D). When stratified by both prior treatment status and response, the fold 
change in CDR3 richness per VJ combination was associated with benefit in Ipi-P but not 
Ipi-N patients (p = 0.014 versus p = 0.287; Figure S5E), while a significant decrease in 
CDR3 evenness per VJ pair was observed in Ipi-N but not Ipi-P benefiting patients (p = 
0.020 versus p = 0.131; Figure S5D). These results, derived from CDR3 subsets grouped by 
VJ combination, are mostly consistent with the trends of bulk CDR3 populations (Figure 
5B). This suggests, due to association with CDR3 amino acid sequences rather than VJ 
cassette identities, that T-cell population diversity dynamics are driven substantially by 
antigen recognition.
To visualize these changes in CDR3 diversity within each VJ combination, CDR3 evenness 
per VJ versus number of CDR3s per VJ were plotted for every VJ cassette group pre- and 
on-therapy as kernel density plots (Figure 5D). In the Ipi-N cohort, rightward shifts along 
the x-axis represent increases in CDR3 richness per VJ combination on-therapy and 
downward shifts along the y-axis represent decreases in CDR3 evenness per VJ combination 
on-therapy. Notably, the shifts in evenness and richness per VJ are less prominent in the Ipi-
P cohort.
Integrated T-Cell Abundance and Diversity Metrics Associated with Response
—Due to the diversity of the TCR repertoire in circulating blood (Zarnitsyna et al., 2013), 
increased T-cell infiltration is usually concomitant with an increase in the observed diversity 
of that TIL repertoire. To understand whether the changes observed in the TIL CDR3 
repertoires during Nivo therapy were primarily a function of the degree of infiltration or 
were due to clonotype distribution changes, indicative of selection and expansion of T-cell 
clonotypes, the minimum percentage of unique CDR3 sequences accounting for 90% of the 
sequencing reads (D90) was calculated for each TIL sample. D90 is an indicator of evenness 
in which lower values indicate a more skewed distribution. While the evenness of most Ipi-P 
TIL repertoires did not change on-therapy, evenness varied widely among Ipi-N patients 
(Figure 5E). D90 value versus the level of TIL infiltration showed that in Ipi-N patients, 
disease control was greater among patients with lower TIL D90, including several with low 
TIL infiltration, such as patients 10, 89, and 94 (Figure 5E). This likely reflects the 
Riaz et al. Page 8
Cell. Author manuscript; available in PMC 2018 November 02.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
expansion of specific clonal populations in Nivo responders. This behavior contrasted with 
that of the Ipi-P cohort, in which high fractional TIL levels during Nivo therapy were a 
strong indicator of disease control, but CDR3 diversity varied relatively little (Figures 5E 
and S5A). Furthermore, usage of CD8-associated V-segments (Emerson et al., 2013) was 
significantly correlated with response (p = 0.005; ordinal regression), while CD4-associated 
V-segments were not (p = 0.329; ordinal regression; Figure 5F).
Integrative Analysis of Tumor and T-Cell Dynamics
Changes in T-Cell Diversity Associate with Tumor Neoantigen Landscape—We 
next assessed how the underlying changes in T-cell clonal dynamics related to changes in the 
clonal dynamics of the tumor. Changes in T-cell repertoire evenness were directly 
proportional to changes in the fraction of clonal mutations in patients with CR/PR and PD. 
Notably, there was a trend for a positive relationship in responders (p = 0.07), but a negative 
relationship in patients with PD (p = 0.08; Figure 6A). We therefore evaluated the 
relationship between the number of T-cell clones that expanded on-therapy and the number 
of neoantigens that became undetectable on-therapy. In patients with CR/PR there was a 
linear relationship between the number of expanded T-cell clones and the number of 
neoantigens that became undetectable on-therapy (p = 0.03) (Figure 6B; Table S5B). 
Notably, this did not occur in patients with SD or PD, suggesting a qualitative difference in 
the T-cell response in these tumors. Similar results were obtained when considering clonal 
mutations that became undetectable on-therapy, pre-therapy mutation load, or genomic 
contraction/persistence cases, supporting the view that T-cell expansion is related to the 
underlying genetic profile of the tumor (Figures S6A–S6C).
Selective Depletion of Antigenic Mutations On-therapy in Responding Patients
—To investigate whether mutations that were undetectable on-therapy were more likely to 
be neoantigens or missense mutations than nonantigenic or synonymous mutations, the 
neoantigen ratios of mutations that produce predicted neoantigens to those that do not were 
compared between mutations detected solely on-therapy and those detected solely pre-
therapy. We hypothesized that the ratio of neoantigen-producing mutations would be higher 
pre-therapy versus on-therapy in patients with an active immune response, indicating 
selective pressure against the generation of antigenic mutations. Patients with CR/PR had 
lower neoantigen ratios on-therapy than patients with PD (p = 0.03; Wilcoxon rank-sum 
test), and patients with SD had a borderline association (p = 0.11; Wilcoxon rank-sum test; 
Figures 6C and S6D).
To evaluate the possibility of selective depletion of putative neoantigens within each 
individual patient, the pre-therapy number of neoantigens per synonymous mutation was 
determined, and the expected number of neoantigens on-therapy was computed using the 
measured number of on-therapy synonymous mutations (see Methods). In patients with 
CR/PR, the observed number of neoantigens was lower than the expected value (p < 0.05; 
Figure S6E), suggesting that T cells were effective in eliminating tumor cells expressing 
immunogenic neoantigens.
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DISCUSSION
Previous reports indicate that increased tumor mutation load is associated with response to 
immune checkpoint therapy and that this relationship improves with assessment of clonality 
(McGranahan et al., 2016; Rizvi et al., 2015; Snyder et al., 2014). We observed an 
association of pre-therapy tumor mutation load and clonal mutation load with survival and 
response; however, this observation was limited to the Ipi-N subset of patients, consistent 
with previous findings (Weber et al., 2016a). Ipi-P patients had significantly more subclonal 
mutations present, and neither of these genomic markers correlated with response to therapy 
in these patients. These findings suggest that current biomarkers used to determine which 
patients will respond to immunotherapy may be more useful for Ipi-N patients than Ipi-P 
patients, though larger studies will be necessary to confirm these findings.
After 4 weeks of Nivo therapy, we observed a marked decrease in detectable mutations 
among patients with CR/PR and a moderate decrease in patients with SD. Clonality analysis 
identified that Nivo therapy affects the evolutionary landscape of tumors in patients with 
CR/PR, leading to the collapse of whole clonal populations, while in patients with SD, Nivo 
may shift the landscape in favor of specific subclones. Notably, in several patients with SD, 
some subclones became undetectable while others remained. In addition, we demonstrated 
genomic evidence of effective immune elimination of tumor cells containing non-
synonymous mutations and neoantigens on-therapy in responding patients as a group, and in 
a subset of responding patients individually. Moreover, T-cell clones expanded in proportion 
to the number of neoantigenic mutations that became undetectable on-therapy. These 
observations agree with evidence of immune-mediated genetic loss of patient-specific 
mutations, such as after adoptive T-cell therapy (Verdegaal et al., 2016). Our genetic data are 
consistent with immunoediting, and are derived from a larger group of patients than 
previously studied (Verdegaal et al., 2016). However, we cannot make definitive conclusions 
due to computational limitations; namely, unambiguous identification of specific 
neoantigens driving this effect.
Therapy-induced clonal evolution has been reported following other cancer therapies such as 
cytotoxic treatments in glioblastoma (GBM) and chronic lymphocytic leukemia, and our 
observation of CDKN2A loss in four patients with PD agrees with reported changes in GBM 
tumors at progression (Johnson et al., 2014; Landau et al., 2015). The appearance of new 
mutations on-therapy could represent genetic drift, or alternatively could be consistent with a 
model in which certain subclonal populations are selected under immunologic pressure. 
However, on-therapy expression analysis indicates that an immune ignorance or immune 
exclusion mechanism of resistance is likely operative rather than the evolution of an intrinsic 
genetic mechanism mediating resistance. The early collapse in clonal populations among 
responding patients is consistent with previous findings (Landau et al., 2015; Wang et al., 
2016), and suggests that clonal composition undergoes significant changes after cytotoxic 
therapy. Our results may potentially be affected by variation in the anatomic location from 
which the tissue was taken and by intratumoral heterogeneity, and by decreased purity in on-
therapy biopsies; however, biopsies targeted the same site and, although purity did decrease 
on-therapy, the magnitude of change was not large enough to explain observations herein.
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Expression analysis of pre-therapy tumor samples identified a small set of upregulated 
immune-related genes in responders, consistent with prior reports demonstrating an IFN-γ 
signature associated with response (Taube et al., 2012; Taube et al., 2015). However, these 
expression changes were only marginally predictive of response. Notably, consistent with 
previous findings (Larkin et al., 2017; Weber et al., 2016b), of patients who received prior 
immunotherapy, only those with PD-L1-expressing or immunologically “hot tumors” 
appeared to respond whereas significant responses were observed among PD-L1 low to no 
expression subgroups among Ipi-N patients. These findings may again be limited due to the 
size of the cohort but, like mutation load and tumor clonality, suggest that the importance of 
a “hot tumor” may depend on prior therapy received.
Surprisingly, stratification based on a molecular phenotype of response (i.e., genomic 
contraction/persistence) demonstrated a more pronounced difference in pre-existing 
immunity between molecular responders and non-responders. Genes differentially expressed 
between groups could predict survival in other patients in this dataset and in other 
immunotherapy-treated cohorts, signifying their biologic relevance and suggesting that 
delays in clinical response may be secondary to immune infiltration (Wolchok et al., 2009). 
This highlights the difficulty in relying solely on clinical and radiographic response to 
understand the underlying biologic mechanisms of response to therapy in human tumors. 
Notably, this analysis identified numerous HLA class II genes, along with other genes, as 
differentially expressed, similar to a recently reported signature indicating differences in 
regulation of macrophages (Kaneda et al., 2016). Changes in macrophages on-therapy also 
associated with clinical response (Figure 4D), suggesting that macrophages may play an 
important role in response (Gordon et al., 2017).
Analysis of on-therapy expression changes revealed marked upregulation of a multitude of 
immune pathways that were more pronounced in responding patients, and included 
additional checkpoints and a broader set of DEGs than previously reported (Chen et al., 
2016). Some of these newly identified gene products may be considered as candidate targets 
for future combination immunotherapy trials. Most patients with PD had minimal immune 
response on-therapy, and differential gene analysis did not identify a dominant or single 
method of tumor-intrinsic immune evasion, suggesting an immune ignorance or immune 
exclusion mechanism rather than an adaptive resistance mechanism (Salerno et al., 2016; 
Spranger et al., 2013) (Figure 4B). In contrast, many patients with SD appeared to have 
modest immune response induction, suggesting that an adaptive mechanism of resistance 
may have a more important role in these patients (Taube et al., 2012; Taube et al., 2015).
Increased cytolytic activity, indicative of T-cell activation, associated with response. Both 
cytolytic activity and response were observed at similar rates regardless of prior immune 
therapy exposure. However, analysis of T-cell repertoires suggested that anti-PD-1 response 
is associated with different patterns of T-cell diversity dynamics in Ipi-N versus Ipi-P 
patients. We infer that decreased evenness without a significant change in the total number 
of CDR3s (richness) observed in Ipi-N responders is consistent with expansion and 
accumulation of specific T-cell clonotypes in response to the detection of tumor antigens. 
We speculate that TILs of Ipi-P patients may represent a binding repertoire already 
differentially selected by the tumor antigenic landscape during Ipi treatment, but 
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subsequently exhausted through PD-1/PD-L1 signaling. The predictive value of exhaustion 
marker expression for responsiveness in Ipi-P but not Ipi-N patients is consistent with this 
model (Figure 3B). Thus, we speculate that in Ipi-P patients, anti-PD-1 therapy functions 
mainly by alleviating exhaustion among the extant distribution of TIL clonotypes, while in 
Ipi-N patients, anti-PD-1 therapy facilitates selective intratumoral expansion of tumor-
reactive clonotypes (Figure 6D).
We hypothesize that changes in T-cell repertoire diversity are associated with anti-PD-1-
induced intratumoral clonal architecture changes, reflecting the cytolytic anti-tumor effect of 
expanded tumor antigen-specific T-cell clonotypes. Of note, changes in T-cell repertoire 
evenness were directly proportional to changes in the fraction of clonal mutations in 
responders and patients with PD. There was a trend for a positive and negative relationship 
in responders and non-responders, respectively, suggesting that in responders, as T-cell 
clones expand, clonal mutations are targeted and eliminated. Possible explanations for the 
negative relationship in non-responders include: (1) T-cell clonotypes that expand may target 
subclonal mutations instead of clonal mutations, resulting in a futile T-cell response (Figure 
S6F), or (2) decreased T-cell repertoire evenness could be due to clonal expansion of 
regulatory T cells, which may enhance an immunosuppressive environment.
In conclusion, we performed extensive immunogenomic analyses on melanoma samples 
treated with anti-PD-1 therapy and characterized how tumor genomic and 
microenvironmental features changed over time. Assessment of the genomic landscape on-
therapy demonstrated clonal evolution consistent with therapy-dependent immunoediting. T-
cell repertoire analysis identified that T-cell clonotypes expand in proportion to the number 
of neoantigens that become undetectable in responding patients. Gene expression analysis 
revealed the changing transcriptional and microenvironmental alterations induced by anti-
PD-1 therapy and identified a broad spectrum of immune checkpoint-related genes that were 
upregulated. These data have important implications for understanding the mechanism of 
action of checkpoint inhibitors and for the design of future immune checkpoint blockade 
trials. Based on our observations, we propose a model of tumor evolution and its 
microenvironment in response to anti-PD-1 therapy (Figure 6D).
STAR METHODS
CONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for resources and reagents should be directed to and will be 
fulfilled by the Lead Contact, Timothy Chan (chant@mskcc.org). Sequencing data may be 
accessed, on approval, by individual investigators upon request (https://fasttrack.bms.com 
and christine.horak@bms.com).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Eighty-five patients were accrued to a multi-arm, multi-institutional, institutional-review-
board-approved, prospective study (CA209-038; NCT01621490) to investigate the 
pharmacodynamic activity of Nivo. All patients received Nivo (3 mg/kg every 2 weeks) until 
progression or for a maximum of 2 years. Radiographic assessment of response was 
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performed approximately every 8 weeks until progression. Progression was confirmed with 
a repeat CT scan typically 4 weeks later. Tumor response for patients was defined by 
RECIST v1.1. Response to therapy indicates best overall response unless otherwise 
indicated. All patients underwent biopsy before commencing therapy (1–7 days before first 
dose of therapy) and underwent a repeat biopsy, collected from the same site, on cycle 1, day 
29 (between days 23–29). Tumor tissue was divided for FFPE and storage with RNAlater® 
(Ambion) for subsequent RNA/DNA extraction. Of 85 patients, 68 had sufficient material 
for genomic analysis. 35 of 68 patients were Ipi-P and 33 were Ipi-N. Different subsets of 
patients had sufficient material for the different genomic analysis described (Tables S2 and 
S4). Of the 68 patients studied, the median patient age was 55 years (range 22–89) and 
consisted of 1 M0, 13 M1a, 10 M1b, 36 M1c and 8 patients with unknown stage at study 
entry.
METHOD DETAILS
Whole-Exome Sequencing—DNA was extracted from samples stored with RNAlater® 
and sequenced with next-generation sequencing. Sequencing libraries were generated using 
Illumina’s in-solution DNA probe based hybrid selection method as previously described 
(Fisher et al., 2011). Exonic sequences were enriched using Agilent SureSelect All Exon V2. 
Pooled libraries were normalized to 2 nM and denatured using 0.2 M NaOH prior to 
sequencing. Sequencing was performed per manufacturer’s protocols using either the HiSeq 
2000 V3 or HiSeq 2500. Each run was a 76bp paired-end with a dual eight-base index 
barcode read. Alignment and removal of duplicates was performed as previously described 
(Riaz et al., 2016b). A combination of four different mutation callers (MuTect 1.1.4, 
SomaticSniper 1.0.4, VarScan 2.3.7, and Strelka 1.0.13) were used to identify SNVs. SNVs 
with an allele read count of less than 5 or with corresponding normal coverage of less than 7 
reads were filtered out as previously described (Riaz et al., 2016b). Small insertions and 
deletions (indels) were determined using VarScan 2.3.7 and Strelka 1.0.13. Mutation load 
was determined as the number of remaining non-synonymous mutations. A previously 
published cutoff of 100 mutations was used to segregate high from low mutation-load 
tumors (Snyder et al., 2014). Only high- or moderate-impact indels determined by both 
callers were selected. Mutational subtypes of melanoma were determined using the TCGA 
classification system. Previously described signatures of mutational processes were 
determined in each sample using non-negative least squares regression as provided by the R 
package deconstructSigs v1.8.0 using the COMISC signatures as the mutational signature 
matrix.
Neoantigen Analysis—High-resolution HLA typing was performed computationally 
using SOAP-HLA from exome sequencing (exome-seq) data. Each non-synonymous SNV 
was translated into a 17-mer peptide sequence, centered on the mutated amino acid. 
Adjacent SNVs (such as those induced by UV irradiation) were first corrected for using 
MAC. Subsequently, the 17-mer was then used to create 9-mers via a sliding window 
approach for determination of MHC class I binding. NetMHC v4.0 was used to determine 
the binding strength of mutated peptides to patient-specific HLA alleles. All peptides with a 
rank <2% were considered for further analysis. If one mutation generated multiple 9-mer 
peptides that bound to patient-specific HLA alleles, it was only counted as one neoantigen 
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(i.e., one mutation could only generate a single predicted neoantigen). We considered 
neopeptides as the total number of predicted 9-mers that bound to patient-specific HLA 
alleles (i.e., one mutation can generate multiple neopeptides).
To test whether the observed number of neoantigens was different from the expected count 
in each on-therapy tumor sample, we empirically calculated the following baseline rates pre-
therapy:
1. The average number of missense mutations per silent mutation across tumors.
2. The number of neoantigens per missense mutation. Of note, since computational 
tools that predict neoantigens are dependent on patient-specific HLA class I 
alleles and some HLA-I alleles can bind greater numbers of peptides than others, 
we calculated this rate specific to the patient, rather than an average across all 
patients.
Using these two baseline rates, we used the number of silent mutations in each on-therapy 
tumor sample to calculate the expected number of neoantigens. Hence, the expected number 
of neoantigens in an on-therapy tumor sample is equal to the number of silent mutations in 
an on-therapy tumor sample multiplied by the number of missense mutations per silent 
mutation pre-therapy, multiplied by the number of neoantigens per missense mutation in the 
patient’s tumor sample pre-therapy. The chi-squared test was used to determine whether the 
observed number was different from the expected value. All the calculations were done 
using R statistical software
Copy-Number Analysis—Allele-specific copy-number analysis was performed from 
exome-seq data using FACETS v0.5.0 with a critical value of 300 to increase the strictness 
of segments. The fraction of the copy-number-altered genome was defined as the fraction of 
the genome with either non-diploid copy-number or evidence of loss of heterozygosity. 
Homozygous copy-number alterations in CDKN2A, NF1, PTEN, and B2M were manually 
reviewed and, when available, confirmed with corresponding expression changes. Recurrent 
copy-number alterations for melanoma as determined by GISTIC were downloaded from 
The Broad Firehose on January 28, 2016, and evaluated in each sample for presence or 
absence using copy-number data generated by FACETS.
We additionally assessed genomic instability as previously described (Davoli et al., 2017). 
Each genomic segment in the FACETS output was assigned a somatic copy-number 
alteration (SCNA) level on a five-tier scale based on the total copy-number (tcn) and sample-
ploidy values. Specifically, a ploidy-adjusted tcn value, T, was computed by rounding the 
sample’s ploidy value to the nearest whole number and subtracting it from the tcn.em value 
(calculated by FACETS software EM algorithm). Genomic segments were classified as 
below:
SCNA Level SCNA Event Ploidy-Adjusted tcn
2 Deep amplification T ≥ 3
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SCNA Level SCNA Event Ploidy-Adjusted tcn
1 Amplification 3 > T ≥ 1
0 Neutral 1 > T > −1
−1 Deletion −1 ≥ T
−2 Deep deletion Ploidy = −T
Chromosomal, chromosome-arm and focal SCNA scores were derived for each sample. 
SCNA events were determined to be chromosomal if segments with the same SCNA level 
accounted for at least 75% of the total length of FACETS segments for a given chromosome. 
Segments determined not to be part of a chromosomal event were next evaluated as 
potentially contributing to chromosome-arm events by checking if genomic segments 
sharing the same SCNA level overlapped with at least 75% of the chromosome arm’s 
coordinates. Segments determined not to be contributing to chromosomal events or to 
chromosome-arm events were defined as focal SCNA events if their individual lengths were 
less than half the length of chromosome arms on which they were located. SCNA scores for 
each level were computed by individually summing the absolute values of the chromosome, 
arm and focal events. SCNA scores were normalized across all samples using the mean and 
standard deviation. An additional SCNA score was computed by adding the normalized 
chromosome and arm level SCNA scores.
Tumor Clonality Analysis—We determined the CCF of mutations identified in each 
tumor sample using PyClone v0.13.0, as previously described (Morris et al., 2016). For each 
SNV, CCF was estimated based on reference and variant allele read counts as well as allele-
specific copy-number information determined by FACETS as described above. Tumor purity 
was also estimated using FACETS and provided as an input to PyClone. The infinite beta 
binomial mixture model with default priors was fit after 10,000 iterations. As in previous 
work, we considered mutations to be clonal if the 95% confidence interval (CI) of the CCF 
contained 95% (McGranahan et al., 2015). The CCF was calculated for every SNV in a 
sample and represents an estimate of the fraction of cancer cells carrying that mutation. The 
CCF was calculated for each SNV separately based on variant allele frequencies (VAFs), 
copy-number status (amplifications/deletions), ploidy of the genome, and purity of the 
sample, and can be interpreted as an adjusted VAF, which allows comparison of SNVs 
across different samples. We classified SNVs into clonal and subclonal variants depending 
on the CI of the CCF estimation. SNVs for which the lower bound of the CI exceeded 95% 
were considered clonal mutations, others subclonal. A comparison based on CCFs 
determined by ABSOLUTE provided similar results (data not shown) (Carter et al., 2012). 
High versus low clonal mutation load was split at the median of the clonal mutation load for 
the cohort.
SNVs were considered to indicate genomic expansion if their subclonal CCF increased by at 
least 10% from pre- to on-therapy sample or if they were novel to the on-therapy sample and 
did not occur in pre-therapy sample. SNVs indicating genomic contraction decreased by 
≥10% CCF or were only identified in the pre-therapy sample but not in the on-therapy 
sample. SNVs that occurred at clonal or subclonal CCFs within 10% of pre- and on-therapy 
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samples were not considered to indicate mutational changes and referred to as genomic 
persistence. A comparison of the selective pressure per sample, was defined as the fraction 
of mutations undergoing genomic contraction subtracted from the fraction of mutations 
undergoing genomic persistence. This metric was used for subsequent survival analysis and 
RNAseq differential gene expression analysis.
RNA Sequencing—RNA was extracted from tissue specimens stored using RNAlater®. 
Raw FASTQ files were aligned on the hg19 genome using the STAR aligner with default 
parameters. Aligned fragments were then counted and annotated using Rsamtools v3.2 and 
the TxDb.Hsapiens.UCSC.hg19.knownGene transcript database, respectively. Normalized 
fragments per kilobase per million mapped reads (FPKM) were obtained using the robust 
FPKM estimate function of DESeq2 v1.12.4. Raw reads were normalized with regularized-
logarithm transformation function with robust estimation and used to construct a PCA plot, 
which was manually reviewed. Patient 3 was considered an outlier (data not shown) and thus 
removed from subsequent transcriptome analysis. All differential gene analysis was 
conducted using the DESeq2 package.
Differential gene expression analysis was performed using a generalized linear model with 
the Wald statistical test, with the assumption that underlying gene expression count data 
were distributed per a negative binomial distribution with DESeq2. DEGs were considered 
for further analysis with a q-value <0.20. Clustering of DEGs was conducted with hierarchal 
clustering (Euclidean distance followed by Ward agglomeration algorithm) primarily to 
segregate upregulated and downregulated genes.
For pre-therapy samples, we considered DEGs between responders (CR/PR) compared with 
non-responders (PD) or patients with SD without adjusting for any other parameters. For 
analysis of pharmacologic response, we compared the subset of samples with paired on- and 
pre-therapy RNA-seq to identify genes that had changes in expression on-therapy. We 
grouped patients as those who benefited (CR/PR/SD) and those who had no benefit (PD) to 
identify genes that changed differentially. Design matrices for each analysis are available in 
supplementary code available on GitHub.
GO enrichment analysis was performed with the R package clusterProfiler, with a 
Bonferroni correction and an adjusted p-value of 0.20 (Yu et al., 2012). Fold changes from 
analysis of RNA-seq data were inputted to IPA. The IPA downstream effects analysis was 
used to identify differentially regulated pathways.
Cytolytic activity was determined as the geometric mean of genes GZMA and PRF1 as 
previously described (Rooney et al., 2015). Similarly, a signature of IFN-γ was determined 
for each sample set using a set of genes previously described (Chiappinelli et al., 2015). To 
further refine subsets of immune cells that were present in each sample, CIBERSORT was 
used to conduct immune deconvolution on the FPKM values of each patient.
TCR β-Chain Sequencing and Analysis—Tumor biopsy samples were collected prior 
to and 4 weeks after initiation of Nivo therapy and stored in RNAlater®. DNA was extracted 
and submitted to Adaptive Biotechnologies for survey level TCR β-chain sequencing 
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(Carlson et al., 2013; Robins et al., 2009), where targeted amplicon libraries were prepared 
by multiplex PCR targeting all TCR β-chain V and J gene segments, and sequenced using 
the Illumina HiSeq system. Data for individual TCR sequences, including V and J gene 
segment identification and CDR3 sequences, were obtained from Adaptive Biotechnologies 
for customized analysis of T-cell repertoire diversity dynamics.
Population diversity of the T-cell repertoire can be characterized and quantified by two 
separate factors: richness (i.e., the number of unique elements in a population), and evenness 
(i.e., the distribution of the frequencies of those elements). Shannon entropy (H) takes into 
account both richness and evenness, but gives more weight to evenness (Arnaud-Haond et 
al., 2007). Evenness is defined as the observed H divided by the maximum possible H, given 
the number of unique elements in a population. High evenness (on a scale of 0 to 1) implies 
that all elements are nearly equally distributed, while low evenness is indicative of 
population skewing, or, in the case of TCR repertoire analysis, biased expansion of 
individual T-cell clonotypes (Arnaud-Haond et al., 2007; Six et al., 2013). Clonality is 
defined as the complement of evenness (i.e., 1 – evenness). As such, these terms are used 
somewhat interchangeably, but with reversed scales. Note that for analysis of evenness, two 
outlier cases were removed as determined by Grubbs’ Test, alpha = 0.1.
The protein-binding characteristics of the CDR3 antigen-binding region of the TCR can be 
studied in a more targeted way by analyzing the repertoire of amino acid CDR3 sequences 
encoded by each combination of V and J cassettes. To explore whether the global TCR 
diversity dynamics described above could also be detected at the level of individual VJ 
cassette combinations, we determined CDR3 richness and evenness for every VJ pair, as 
previously described (Sims et al., 2016). This approach, although more rigorous, is an in-
silico descendant of traditional spectratyping, in which specific V and J cassette primers are 
used to amplify all CDR3s encoded by specific VJ cassette combinations and the products 
are analyzed by electrophoresis (Arstila et al., 1999). The benefits of this in-silico approach 
are two-fold: 1) by examining diversity dynamics at the VJ cassette level, bias potentially 
introduced by preferential V and J cassette primer binding is diminished, and 2) a greater 
understanding of the extent to which antigen-binding properties (CDR3 amino acid 
sequences) versus VJ cassette usage biases influence global changes in TCR diversity is 
gained (Sims et al., 2016). Kernel density estimate plots of the number of CDR3s per VJ 
versus evenness of CDR3s per VJ were generated using the seaborn statistical data 
visualization platform for Python.
Significantly expanded T-cell clones were identified using the immunoSEQ® Analyzer from 
Adaptive biotechnologies®, per the method previously described (DeWitt et al., 2015); 
briefly, Fisher’s exact test was used to generate a p-value by for every T cell clone, and P-
values were corrected using a positive false discovery rate method to identify significantly 
expanded T-cell clones.
Immunohistochemistry—PD-L1 staining was evaluated centrally by IHC using a rabbit 
monoclonal anti-human PD-L1 antibody (clone 28-8) and an automated staining procedure 
developed by Dako (Dako, 2016). The percentage PD-L1 expression was scored by a 
qualified pathologist in samples with a minimum of 100 viable tumor cells. Positive PD-L1 
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staining was defined as complete circumferential or partial linear plasma membrane staining 
of tumor cells. Expression of lymphocytic markers within tumor tissue sections was 
centrally assessed by IHC using antibodies against CD3, CD4, CD8 and FOXP3: clone 
LN10 (Leica), clone 4B12 (Dako), clone C8/144B (Dako) and clone 236A/E7 (Abcam), 
respectively. Duplex chromogenic IHC assays consisting of CD3 and CD8, CD3 and CD4, 
and CD3 and FOXP3 anti-human antibodies were established. Percentage expression of each 
marker was estimated using digital image analysis algorithms from multispectral images of 
representative 20 fields in a region of interest that included cancer cells.
Tumor Purity Assessment—Tumor purity was assessed computationally in all paired 
samples using estimates derived from exome-seq data and from RNA-seq data 
independently using OncoSNP-SEQ and ESTIMATE. There was a modest decrease in tumor 
purity in samples with a more significant clinical response than those with PD using any of 
the three methods for estimation of purity (Figure S2D).
We performed a simulation to determine our power to detect a mutation, assuming a five-
fold decrease in purity. We assumed that to accurately call a mutation, five reads with the 
mutation needed to be present and reads were distributed according to a binomial 
distribution (B(n,p)), where n corresponds to the coverage of sequencing and p the true VAF 
of the mutation. At 150× coverage we had 95% power to detect a mutation with a VAF of 
6% or greater and at 300× coverage we had 95% power to detect a mutation of 3% VAF or 
greater in any one sample (Figure S2E). We then computed the proportion of mutations we 
would anticipate to detect using 300× coverage and a fivefold decrease in purity and 
observed a significant depletion in the number of anticipated mutations in most cases 
(Figure S2F). In all cases, the expected number of mutations was larger than the observed, 
which is unlikely given a five-fold decrease in purity (p = 0.004; Wilcoxon rank-sum test).
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistics and Survival Analysis—Survival analysis was conducted with the Kaplan–
Meier method, and continuous data were in general split at the median, unless prior 
thresholds had been established. The log-rank test was used to determine statistical 
significance. Comparison of values between response groups was performed with the 
Wilcoxon rank-sum test unless otherwise specified. Comparisons in Figures 5 (except 5F) 
and S6 were Mann–Whitney test by GraphPad Prism for unpaired data or Wilcoxon 
matched-pairs signed rank test by GraphPad Prism for paired data. All other statistical 
analyses were performed in the R Statistical Computing environment v3.3.1 (http://www.r-
project.org).
DATA AND SOFTWARE AVAILABILITY
See key resources table. The human sequencing data (WES, RNA-seq, TCR-seq) are 
deposited into a controlled-access database managed by Bristol-Myers Squibb. Sequencing 
data may be accessed, on approval, by individual investigators upon request (https://
fasttrack.bms.com and christine.horak@bms.com). The online version of the paper will be 
updated to include the accession numbers once they are available. Code and additional 
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processed data to reproduce key results contained within the manuscript are available at 
https://github.com/riazn/bms038_analysis.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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HIGHLIGHTS
• A prospective trial reveals molecular actions of anti-PD-1 therapy
• Anti-PD-1 therapy induces changes in the mutational burden of tumors
• Distinct changes in gene expression programs associate with clinical response
• Shifts in the TCR repertoire occur following immune checkpoint blockade
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Figure 1. Genomic Features and Sculpting of the Tumor Mutational Landscape by 
Immunotherapy
(A) Baseline genomic characteristics of melanoma tumors from patients treated with 
immune checkpoint therapy. An OncoPrint image of WES data for the cohort sorted by 
response group (CR/PR, SD, PD). The OncoPrint displays genes recurrently mutated in 
melanoma and genes that have been recently associated with response to therapy.
B) Left: Analysis of clonality in pre-therapy samples identifies a trend toward more 
subclonal mutations in Ipi-P patients (p = 0.08; Mann–Whitney test; see also Figure S1A). 
Right: OS in Ipi-N patients by mutation load (high mutation load defined as >100 
mutations).
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(C) Waterfall plot of change in mutation (non-synonymous) and putative neoantigen load 
between pre-therapy biopsy and cycle 1, day 29 on-therapy biopsy by response status.
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Figure 2. Changes in Tumor Clonal Composition after Treatment with Nivo Therapy
(A) Changes in CCF of mutations (synonymous and non-synonymous, clonal/subclonal) 
from pre- to on-therapy samples. Similar CCFs in both pre- and on-therapy samples 
(genomic persistence) in gray; increased CCF or novel in on-therapy samples (genomic 
expansion) in pink; decreased CCF/lost in on-therapy samples (genomic contraction) in blue.
(B) Lost mutations indicating genomic contraction were ubiquitous in CR/PR samples, and 
significantly more frequent in patients with SD than PD. Persistent mutations were less 
common in samples without response and not significantly different between patients with 
Riaz et al. Page 27
Cell. Author manuscript; available in PMC 2018 November 02.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
SD and PD. Variant gains (genomic expansion) were significantly more frequent in patients 
with PD than SD. Data are presented as median and interquartile range (IQR).
(C) Left: Waterfall plot of net change between fraction of mutations representing genomic 
contraction and genomic persistence. Right: OS and PFS by genomic contraction and 
genomic persistence (p = 0.003; log-rank test and p = 3.34e–4; log-rank test, respectively).
(D) Changes of CCF in representative cases from patients with CR/PR (patient 53), SD 
(patient 10) and PD (patient 27). Tree diagrams illustrate the relationships between the 
clones. Colored lines and circles denote specific clones.
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Figure 3. Pre-therapy Tumor Gene Expression Analysis
(A) Hierarchal clustering analysis of DEGs in tumors from pre-therapy biopsies.
(B) Heatmap associations of gene expression signatures in the Ipi-P and Ipi-N cohorts.
C) Analysis of DEGs in tumors with genomic contraction versus those with genomic 
persistence (n = 26).
(D) Left: Clustering of the entire cohort of patients (n = 45) by DEGs identified in (C) 
clusters patients into two groups in entire cohort and into four groups in combined Hugo et. 
al. and Van Allen et. al. cohorts. Right: Long-term OS associates with clustered groups of 
patients from the entire cohort and from the combined Hugo et al. and Van Allen et al. 
cohorts.
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Figure 4. Changes in Gene Expression Following Nivo Therapy
(A) Left: Analysis of ratio of DEGs and selected genes between pre- and on-therapy 
samples. Right: Examples of genes that change after initiation of Nivo.
(B) Analysis of changes in gene expression (on-therapy compared with pre-therapy) that are 
altered in tumors that respond or do not respond to Nivo.
(C) Graphical illustration of key pathways differentially expressed in (B).
(D) Immune deconvolution of RNA-seq data comparing pre- and on-therapy samples. Data 
are presented as median and IQR.
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Figure 5. T-Cell Infiltrate and Repertoire Association with Response to Nivo
Due to the reduced number of cases with paired TCR-seq data, patients with CR/PR and SD 
were grouped as having “benefit”, and patients with PD were considered to have “no 
benefit”.
(A) Change in TIL abundance and activity as measured by multiple methods (DNA-based 
TCR-seq, IHC, and RNA-based cytolytic score). Data are presented as median and IQR.
(B) Change in richness and evenness of intratumoral T-cell repertoires. *Two outliers were 
removed per Grubbs’ test, alpha = 0.1 (see Methods). Data are presented as median and 
IQR.
(C) Median richness and evenness of CDR3s per VJ combinations pre-therapy and on-
therapy (see also Figure S6E).
(D) Kernel density plots of CDR3 evenness versus number of unique CDR3s for every 
observed VJ pair in selected patients.
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(E) Comparison of on-therapy TIL levels with changes in T-cell repertoire evenness (D90, 
defined as the minimum fraction of total unique CDR3 sequences that constitutes 90% of all 
sequencing reads).
(F) Fraction of on-therapy TCR repertoire utilizing V-segments associated with CD8 or CD4 
T cells. Data are presented as mean ± SEM.
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Figure 6. T Cells Expand in Proportion to Depletion of Neoantigens
(A) Changes in T-cell population distribution (i.e., evenness) and changes in tumor mutation 
clonality by response.
(B) Relationship between the number of predicted neoantigens lost and the number of T-cell 
clones expanded on-therapy.
(C) Neoantigen ratios (mutations predicted to generate neoantigens per mutations not 
predicted to generate neoantigens) from mutations solely identified in pre-therapy samples 
compared with those identified solely in on-therapy samples. Data are presented as mean ± 
SEM.
(D) Graphical model depicting changes during anti-PD-1 therapy. (a) Changes in mutations 
and neoantigens during therapy. (b) Changes in TCR repertoire depend on exposure to prior 
immunotherapy. (c) Changes in immune landscape and checkpoints during therapy.
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